<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>曲妥珠单抗主要生产企业 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/qutuozhudankangzhuyaoshengchanqiye/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Wed, 12 Oct 2022 02:46:37 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>曲妥珠单抗主要生产企业 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2022-2031年中国曲妥珠单抗市场研究报告（2021年中国曲妥珠单抗销售额达17.2亿元）</title>
		<link>https://www.yuanzhezixun.com/2022-2031nianzhongguoqutuozhudankang/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Mon, 11 Jul 2022 06:04:31 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[曲妥珠]]></category>
		<category><![CDATA[曲妥珠单抗]]></category>
		<category><![CDATA[曲妥珠单抗主要生产企业]]></category>
		<category><![CDATA[赫赛汀]]></category>
		<guid isPermaLink="false">https://www.yuanzhezixun.com/?p=33145</guid>

					<description><![CDATA[据元哲咨询分析，预计在2022-2031年，曲妥珠单抗在中国的销售情况会有恢复性的增长。除恢复性增长以外，曲妥珠单抗的销售额也会因为价格的降低和市场的扩张而增加。自曲妥珠单抗入市场以来，价格呈明显下降趋势。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
